Bionano Genomics (NASDAQ:BNGO) Cut to Neutral at LADENBURG THALM/SH SH

Bionano Genomics (NASDAQ:BNGO) was downgraded by analysts at LADENBURG THALM/SH SH from a “buy” rating to a “neutral” rating in a note issued to investors on Friday, MarketBeat reports.

A number of other brokerages also recently commented on BNGO. BTIG Research downgraded Bionano Genomics from a “buy” rating to a “neutral” rating in a report on Tuesday, September 10th. Scotiabank restated a “sector perform” rating and issued a $1.00 price objective (down from $6.00) on shares of Bionano Genomics in a report on Wednesday, August 28th.

Bionano Genomics Stock Performance

Shares of NASDAQ:BNGO opened at $0.26 on Friday. The company has a current ratio of 1.63, a quick ratio of 1.11 and a debt-to-equity ratio of 0.04. The company has a 50-day moving average price of $0.37 and a 200-day moving average price of $0.60. The company has a market cap of $22.01 million, a price-to-earnings ratio of -0.05 and a beta of 2.37. Bionano Genomics has a 12 month low of $0.24 and a 12 month high of $2.27.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Virtu Financial LLC bought a new position in Bionano Genomics in the first quarter worth $36,000. Price T Rowe Associates Inc. MD grew its position in shares of Bionano Genomics by 123.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 70,370 shares of the company’s stock worth $79,000 after buying an additional 38,900 shares during the period. Carret Asset Management LLC grew its position in shares of Bionano Genomics by 89.0% in the 3rd quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock worth $39,000 after buying an additional 40,055 shares during the period. GSA Capital Partners LLP bought a new position in shares of Bionano Genomics in the 3rd quarter worth about $46,000. Finally, Cetera Advisors LLC purchased a new position in Bionano Genomics during the 1st quarter valued at about $163,000. Hedge funds and other institutional investors own 11.35% of the company’s stock.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.